BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CRBI - ECPv6.15.1.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CRBI
X-ORIGINAL-URL:https://mycrbi.com
X-WR-CALDESC:Events for CRBI
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221212T100000
DTEND;TZID=America/Toronto:20221212T110000
DTSTAMP:20260624T191113
CREATED:20250313T183535Z
LAST-MODIFIED:20260604T155323Z
UID:1015-1670839200-1670842800@mycrbi.com
SUMMARY:CRBI/CIRC Seminar
DESCRIPTION:CRBI Seminar – Dr. Terry Sachlos\, Associate Professor – Teaching Stream\, York University \nNew paradigm of leukemic stem cells and how they can be targeted using differentiation therapy as novel therapeutic strategy
URL:https://mycrbi.com/event/1015/
CATEGORIES:Seminars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221212T140000
DTEND;TZID=America/Toronto:20221212T150000
DTSTAMP:20260624T191113
CREATED:20221210T192051Z
LAST-MODIFIED:20221210T192613Z
UID:818-1670853600-1670857200@mycrbi.com
SUMMARY:In person seminar with Dr. Sachlos
DESCRIPTION:Acute myeloid leukemia is a fatal blood cancer.  The malignant AML blast cells rapidly overwhelm the bone marrow\, disrupting resident hematopoietic stem cells (HSC) and normal blood production and eventually causing death. Treatment involves the administration of DNA-binding chemotherapeutic agents that indiscriminately kill both HSC and progenitors\, leading to myelosuppression and ultimately drug dose attenuation.  Ideally\, drugs should specifically target AML while sparing healthy HSC to reduce potentially lethal myelosuppression side effects and extend the dosing period.  In this talk\, we will discuss the new paradigm of leukemic stem cells and how they can be targeted using differentiation therapy as a novel therapeutic strategy with reduced side effects.  The development of novel stem cell screening platforms able to identify agents that specifically target AML-leukemic stem cells (AML-LSC) while sparing HSC will be explored.  Recent results demonstrating the importance of engineered niche microenvironments to extend the ex vivo lifespan of HSC and AML-LSC will also be presented.  This work sets the foundations high-throughput 3D organoid drug screening using primary human cells extracted from tumours for the development of precision medicine applications.
URL:https://mycrbi.com/event/in-person-seminar-with-dr-sachlos/
LOCATION:Life Sciences Buliding (LSB) 107
END:VEVENT
END:VCALENDAR